Last reviewed · How we verify

Bimzelx — Competitive Intelligence Brief

Bimzelx (BIMEKIZUMAB) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed Interleukin-17A Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Bimzelx (BIMEKIZUMAB) — Ucb Japan Co., Ltd.. Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bimzelx TARGET BIMEKIZUMAB Ucb Japan Co., Ltd. marketed Interleukin-17A 2021-01-01
Cosentyx secukinumab Novartis marketed IL-17A antagonist Interleukin-17A (IL-17A) 2015-01-01
Cosentyx Cosentyx Janssen Research & Development, LLC marketed Interleukin-17A
Subcutaneous injection of Secukinumab Subcutaneous injection of Secukinumab Peking Union Medical College marketed IL-17A inhibitor (monoclonal antibody) IL-17A (Interleukin-17A)
BIMZELX BIMEKIZUMAB-BKZX UCB INC marketed Interleukin-17A, Interleukin-17F, Interleukin-17AF
Taltz Taltz Yale University marketed Interleukin-17A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bimzelx — Competitive Intelligence Brief. https://druglandscape.com/ci/bimekizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: